Compare AbCellera Biologics Inc (ABCL) vs Intuit Inc. (INTU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Intuit (INTU) trades at $272.14, down 1.17% on the day, amid a bearish technical signal and ongoing securities fraud investigations. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust profitability with a net income margin of 21.91%. Revenue growth is steady, climbing from $12.7B in 2022 to $18.8B in 2025, supported by a high gross profit margin of 79.96%.

Despite solid fundamentals, INTU faces significant headwinds from legal scrutiny and negative sentiment, with a 20% stock drop triggering multiple fraud probes. Analyst consensus remains bullish with a $433.69 price target, but near-term risks from litigation and competitive pressures in tax software could limit upside. The stock's current valuation at a P/E of 16.6 offers a margin of safety if growth persists.